Loading company…
TheraVectys develops lentiviral vector vaccines for cancer and infectious diseases.
Founded in 2005, TheraVectys develops prophylactic and therapeutic vaccines for cancer and diseases including HIV, hepatitis, and malaria. Its platform uses lentiviral vectors. The company is based in Paris, France. In September 2012, it raised EUR 7.5 million (USD 9.6 million) in Series C funding from individual investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in